Novartis Ag

Vijay Sethuraman

Michael Mutz

Mika Lindvall

Heinz Ernst Moser

Robert Lowell Simmons

Rita Ramos

Folkert Reck

Andreas Kordikowski

Zaixing Li

Anthony Casarez

Andreas Fisch

Bernd Ulrich Riebesehl

Nicole Bieri

Philipp Lustenberger

Bin Li

Sisi Zhang

Marc Schoenhentz

Eric Aubin

This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ('hydrates'). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.

Crystalline forms of a TLR7/TLR8 inhibitor

The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

Salts and solid forms of a monobactam antibiotic

Growing community of inventors

Fremont, CA, United States of America

Vijay Sethuraman